Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-09-04
2007-09-04
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S176000, C514S308000, C514S547000
Reexamination Certificate
active
10049393
ABSTRACT:
The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3929813 (1975-12-01), Higuchi et.al.
patent: 5180716 (1993-01-01), Yaksh et al.
patent: 5767112 (1998-06-01), Poli et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840881 (1998-11-01), Uda et al.
patent: 36628 95 (1996-05-01), None
patent: 0 447 171 (1991-09-01), None
patent: 11-246603 (1999-09-01), None
Bom, A. et al “A novel concept of reversing neuromuscular block” Angew. Chem. Int. Ed. (2002) vol. 41, no 2, pp. 266-270.
Adam, J. et al “Cyclodextrin-derived host molecules as reversal agents . . . ” J. Med. Chem. (2002) vol. 45, pp 1806-1816.
Tarver, G. et al “2-O-Substituted cyclodextrins as reversal agents . . . ” Bioorg. Med. Chem. (2002) vol. 10, pp 1819-1827.
Zhang, M. “Drug-specific cyclodextrins . . . ” Drugs of the Future (2003) vol. 28, no 4, pp 347-354.
Lee, C. “Structure, conformation, and action of neuromuscular blocking drugs” Brit. J. Anesth. (2001) vol. 87, no 5, pp 755-769.
B Desire: “Inactivation of sarin and soman by cyclodextrins in vitro” EXPERIENTIA, vol. 43, No. 4, 1987, pp. 395-397.
B. Desire: “Interaction of soman with beta-cyclodextrin” Fundamental and Applied Toxicology, vol. 7, No. 4, 1986, pp. 647-657.
C. May: “Development of a toxin-bindng agent as a treatment for tunicamycinuracil toxicity: protection against tunicamycin poisoning of sheep” Australian Veterinary Journal, vol. 76, No. 11, 1998 pp. 752-756.
K. Uekama: “Effects of cyclodextrins on chlorpromazine-induced haemolysis and nervous systems responses” J. Pharm. Pharmacol., vol. 33, No. 11, 1981, pp. 707-710.
T. Irie: “Protective mechanism of beta-cyclodextrin for the hemolysis induced with phenothiazine neuroleptics in vitro” J. Pharmacobio-Dynamics, vol. 6, No. 6, 1983, pp. 408-414.
International Search Report No. PCT/EP 00/07694 dated Jul. 20, 2001.
Stella, V.J. et al. “Cyclodextrins: Their Future in Drug Formulation and Delivery,” Pharmaceutical Research, vol. 14, No. 5 (1997), pp. 556-567.
Uekama, K. et al. “Cyclodextrin Drug Carrier Systems,” Chem. Rev. (1998) vol. 98, pp. 2045-2076.
Khan, A. R. et al. “Methods for Selective Modifications of Cyclodextrins,” Chem. Rev. (1998) vol. 98, pp. 1977-1996.
Szente, L. et al. “Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development,” Advanced Drug Delivery Reviews (1999) vol. 36, pp. 17-28.
Gattuso, G. et al. “Synthetic Cyclic Oligosaccharides,” Chem. Rev. (1998) vol. 98, pp. 1919-1958.
Miyake, M. et al. “Anionic Cyclophanes as Hosts for Cationic Aromatic Guests,” Tetrahedron Letters, vol. 32, No. 49 (1991) pp. 7295-7298.
Miyake, M. et al. “Biomimetic Studies Using Artificial Systems. VI.1)Design and Synthesis of Novel Cyclophanes Having Eight Carboxyl Groups on the Aromatic Rings2),” Chem. Pharm. Bull., vol. 41(7) (1993) pp. 1211-1213.
Cram, D. J. et al. Macro Rings. VIII. Aromatic Substitution of the [6.6] Paracyclophane1, JAm. Chem. Soc. (1955) vol. 77, pp. 1179-1186.
Soga, T. et al. “Modifications of Hydrophobic Cavity and their Effects on the Complex Formation with a Hydrophobic Substrate,” Tetrahedron Letters, vol. 21 (1980) pp. 4351-4354.
Golden, J.H. “Bi(anthracene-9, 10-dimethylene) (Tetrabenzo-[2,2]-para-cyclophane].,” J. Chem. Soc. (1961) pp. 3741-3748.
Ashton, P. R. et al. “Synthetic Cyclic Oligosaccharides—Syntheses and Structural Properties of a Cyclo[1→4)-α-L-rhamnopyranosyl-(1→4)-α-D-mannopyranosyl] trioside and -tetraoside**,” Chem. Eur. J. (1996) vol. 2, No. 5, pp. 580-591.
Loukas, Y. L., “Measurement of Molecular Association in Drug: Cyclodextrin Inclusion Complexes with Improved1H NMR Studies,” J. Pharm. Pharmacol (1997) vol. 49, pp. 944-948.
Bisson, A. P. et al. “Cooperative Interactions in a Ternary Mixture,” Chem. Eur. J. (1998) vol. 4, No. 5, pp. 845-851.
Jicsinszky, L. et al., “Cyclodextrin Derivatives,” Comprehensive Supramolecular Chemistry, vol. 3, Cyclodextrins, Elsevier Science Ltd., Oxford, UK (1996) pp. 57-188.
Vogtle et al.j, “Cyclophane Hosts: Endoacidic, Endobasic, and Endolipophilic Large Cavities,” Comprehensive Supramolecular Chemistry, vol. 2, Molecular recognition: Receptors for molecular guests, Atwood et al. eds; Elsevier Science Ltd., Oxford, UK (1996) pp. 211-265.
Connors, K.A. “Binding constants, The measurement of Molecular Complex Stability,” Wiley-Interscience, New York (1987) pp. 24-28.
Gennaro, A. R. et al “Parental preparations,” Chapter 84, Remington's Pharmaceutical Sciences, 18thed., Mack Publishing Company (1990) pp. 1545-1569.
Gennaro, A. R. et al “Intravenous admixtures,” Chapter 85, Remington's Pharmaceutical Sciences, 18thed., Mack Publishing Company (1990) pp. 1570-1580.
Patent Abstracts of Japan Translation of JP 11-246603.
Kuroda, Y. et al., “Dynamic Molecular Motions of ρ-Methylcinnamic Acid Included into β-Cyclodextrin Derivatives: A New Type of Free-energy Relationship in Complex Formation,” J. Chem. Soc. Perkin Trans. II, vol. 10 (1989) pp. 1409-1415.
Guillo, F. et al., “Synthesis of symmetrical cyclodextrin derivatives bearing multiple charges,” Bull. Soc. Chim. Fr., vol. 132 (1995) pp. 857-866.
Baer, H. et al., “Heptakis [6-S-(2,3-dihydroxypropyl)-6-thio]cyclomaltoheptaose and its sulfone: water-soluble β-cyclodextrin derivatives having modified polarity,” Carbohydrate Research, vol. 280 (1996) pp. 315-321.
Lindberg B. et al., “Synthesis of some 2-0-(2-hydroxyalkyl) and 2-0-(2,3-di-hydroxyalkyl) derivatives of cyclomaltopheptaose,” Carbohydrate Research, NL, Elsevier Scientific Publishers B.V., Amsterdam vol. 222, No. 1 (1991) pp. 113-119.
Khan A. R. et al., “Methods for Selective Modifications of Cyclodextrins,” Chemical Reviews, US, American Chemical Society, Easton, vol. 98, No. 5, (1998) pp. 1977-1996.
Bom Antonius Helena Adolf
Muir Alan William
Rees David
Hess Susan
Maier Leigh C.
Organon N.V.
LandOfFree
Use of chemical chelators as reversal agents for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of chemical chelators as reversal agents for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of chemical chelators as reversal agents for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787000